Laboratory Testing for Cosmetic Products in the EU: What Is Required and What Is Smart

Regulation (EC) No 1223/2009 governs cosmetic products placed on the European Union market. Article 3 requires safety under normal or reasonably foreseeable conditions of use. Article 10 requires a safety assessment before placing a product on the market, with a cosmetic product safety report prepared in accordance with Annex I. Testing supplies evidence for that assessment; a laboratory certificate alone is not a safety conclusion.

Article 11 requires the responsible person to hold a product information file. The file connects the product description, safety report, manufacturing information, evidence of claimed effects where justified, and relevant animal testing information. The cosmetic product safety report separates safety information in Part A from the assessment and reasoning in Part B. A qualified safety assessor evaluates the evidence, including gaps and the relevance of individual studies.

The practical starting point is therefore a documented product brief. Identify the quantitative formula, ingredient specifications, intended users, application area, foreseeable misuse and final packaging. Agree the outstanding safety questions with the assessor before ordering studies. A test that cannot answer an identified question may add paperwork without reducing uncertainty.

Annex I calls for information on physical and chemical characteristics and stability, microbiological quality, impurities, traces and packaging, exposure and toxicological profiles, among other topics. These are required information areas. They do not create an identical mandatory laboratory programme for every cosmetic. The assessor determines whether existing evidence is sufficient or whether further investigation is necessary.

Commission Implementing Decision 2013/674/EU provides guidelines on Annex I. Its discussion of microbiological quality recognises product characteristics and susceptible populations. Where a preservative challenge test is not performed, the justification must be scientifically defensible. A declaration that a product is natural, concentrated or expensive does not establish microbiological safety.

Separate the legal duty from the chosen evidence route. A supplier specification may support ingredient identity, a finished product study may support stability, and a targeted analysis may investigate a contaminant concern. Record why each source is relevant, what it does not demonstrate and who accepted the rationale. Avoid presenting voluntary standards as legislation.

Stability work should examine changes capable of affecting safety or performance, including appearance, odour, phase separation, pH where meaningful and relevant chemical characteristics. The study design should reflect storage, distribution and use conditions. Accelerated observations can be useful, but their interpretation requires scientific judgement and does not automatically establish a period after opening or durability claim.

Use the intended packaging when assessing compatibility. Interactions with a closure, pump, liner or container can change the formulation or introduce substances. Consider evaporation, leakage, adsorption and migration where relevant. Comparing an unprotected laboratory container with a finished retail pack may miss the exposure pathway that matters.

Document the formula version, batch, container materials, storage conditions and observation criteria. Changes to fragrance, preservative system or packaging can affect previous conclusions. A proportionate change control review decides whether existing stability evidence remains applicable or whether additional work is needed.

Microbiological quality testing describes the condition of a sample when examined. Preservative efficacy testing challenges the protection system under specified conditions. These are complementary questions. An acceptable initial count cannot establish that a water containing product remains adequately protected during foreseeable use.

ISO 17516 addresses cosmetic microbiological limits, while ISO 11930 concerns evaluation of antimicrobial protection. Method suitability matters because preservatives or other ingredients can inhibit recovery during analysis and distort the result. Discuss neutralisation, recovery and the laboratory method with the assessor rather than requesting a generic pass certificate.

Packaging and user behaviour belong in the rationale. A jar repeatedly contacted by fingers presents a different exposure scenario from a protective dispensing system. Products intended for sensitive areas or vulnerable users may require particular consideration. Low microbiological risk must be supported by the formulation and use conditions, not assumed from an oil based description.

Heavy metal or other contaminant screening should follow ingredient origin, processing, supplier controls and plausible exposure. Pigments, mineral materials or botanical ingredients may raise different analytical questions. Article 17 permits the non intended presence of a small quantity of a prohibited substance only where it is technically unavoidable in good manufacturing practice and consistent with Article 3. A detectable trace is therefore not automatically permissible or automatically a failure.

Ask what an analytical panel actually measures. Elemental analysis does not necessarily identify chemical species, and a broad screen may omit the contaminant of concern. Agree suitable methods, reporting conventions and interpretation criteria before sampling. Preserve the evidence needed to connect the finding to the ingredient source and the safety assessment.

Commission Regulation (EU) 2023/1545 amends the fragrance allergen labelling requirements in Annex III of the Cosmetics Regulation. The expanded entries make reliable allergen information and label review important. Verification testing can investigate uncertain composition or supplier information, but the method must cover the substances relevant to the formula. Apply the current entries and transitional provisions to the specific product rather than assuming every fragrance needs the same panel.

Article 20 prevents the use of text, names or other signs implying characteristics or functions a cosmetic does not have. Commission Regulation (EU) No 655/2013 establishes common criteria for justification of cosmetic claims. Evidence should match the actual wording, tested product, target population and conditions of use. Ingredient literature alone may not substantiate a finished product claim.

Hydration, barrier support, microbiome or sensory claims require appropriate endpoints and study designs. An observed laboratory effect should not be translated into a clinical or therapeutic statement without justification. Distinguish an exploratory finding from evidence intended to support a public claim, and evaluate the cosmetic boundary before commissioning an efficacy programme.

Article 8 requires good manufacturing practice. ISO 22716 provides guidance on cosmetic GMP and supports the manufacturing control context. It does not replace product testing, assessor judgement or the product information file. Consistent batch production and traceability help establish whether tested samples represent the product ultimately supplied.

Start with exposure and composition together. Leave on products can involve prolonged contact, while rinse off use changes exposure without removing the need for a safety assessment. Anhydrous and oil based products may have different microbiological risks from water based emulsions, but contamination during manufacture and foreseeable contact with water still deserve attention.

The following planning table is a starting discussion, not a mandatory package or an exemption. Agree the final programme with the safety assessor and laboratory. Record any decision not to test alongside the supporting evidence.

Article 18 establishes the cosmetic animal testing and marketing prohibitions within its scope. A cosmetic testing plan must respect these restrictions. Validated in vitro methods and other non animal evidence can support relevant endpoints, but no individual alternative assay demonstrates complete product safety. The assessor integrates the available information and its limitations.

Before samples leave the site, confirm identification, shipping conditions, method suitability and the intended reporting format. Reports should distinguish measured results from conclusions and document deviations. Keep the underlying studies accessible in the product information file, not only a summary spreadsheet. A defensible programme connects the test question, representative sample, result and safety reasoning.